Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
86Y-IL-13.E13K.D2.Cys
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
86Y-IL-13.E13K.D2.Cys is a radiolabeled research-stage imaging agent consisting of a mutant form of Interleukin-13 (IL-13) conjugated to the positron-emitting radioisotope Yttrium-86 (86Y). The ligand, IL-13.E13K.D2.Cys, is engineered to selectively bind to the Interleukin-13 receptor alpha 2 (IL-13Rα2) with high affinity while avoiding the ubiquitously expressed IL-13Rα1/IL-4Rα heterodimer. IL-13Rα2 is overexpressed in several solid tumors, including glioblastoma, melanoma, and pancreatic ductal adenocarcinoma, but is largely absent in normal tissues, making it an attractive target for tumor-specific imaging and therapy. Developed through a collaboration involving MD Anderson Cancer Center and RadioMedix, this radiotracer is used in PET/CT imaging to non-invasively visualize IL-13Rα2 expression in vivo, supporting the development of theranostic strategies.
- Other names
- Yttrium 86-labelled IL-13-E13K.D2.CysYttrium86-labelled IL-13-E13K.D2.CysYttrium-86-labelled IL-13-E13K.D2.Cys
02
Targets
IL-4R type II (Interleukin-4 receptor type II)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on 86Y-IL-13.E13K.D2.Cys.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 86Y-IL-13.E13K.D2.Cys.